"Grassroots" Suggested Changes Useful But Resource-Intensive - Feigal
This article was originally published in The Gray Sheet
Executive Summary
Agency inspectional programs that were suggested by the Medical Device Industry Initiative Taskforce may need to be re-evaluated by the Office of Regulatory Affairs in light of available resources, according to FDA Center for Devices and Radiological Health Director David Feigal, MD/MPH.
You may also be interested in...
Device Warning Letter Pilot Discontinued; OCC Review Cited As Alternative
The Medical Device Initiative Grassroots Task Force will be briefed regularly on FDA's warning and untitled letter activities, following the agency's decision to end its device center warning letter pilot program
Device Warning Letter Pilot Discontinued; OCC Review Cited As Alternative
The Medical Device Initiative Grassroots Task Force will be briefed regularly on FDA's warning and untitled letter activities, following the agency's decision to end its device center warning letter pilot program
Grassroots Task Force Looks To Guide Firms Making Complaints To CDRH
A Medical Device Industry Initiative Grassroots Taskforce subcommittee is considering whether to develop guidelines for manufacturers that feel they have received unequal treatment by the FDA's Center for Devices and Radiological Health.